dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Miyoshi, Yasuo |
dc.contributor.author | Yoshimura, Yuta |
dc.contributor.author | Saito, Kenichi |
dc.contributor.author | Muramoto, Kenzo |
dc.contributor.author | Sugawara, Michiko |
dc.contributor.author | Alexis, Karenza |
dc.contributor.author | Cortés Castan, Javier |
dc.date.accessioned | 2021-09-16T08:31:26Z |
dc.date.available | 2021-09-16T08:31:26Z |
dc.date.issued | 2020-07 |
dc.identifier.citation | Miyoshi Y, Yoshimura Y, Saito K, Muramoto K, Sugawara M, Alexis K, et al. High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician’s choice—in the EMBRACE study. Breast Cancer. 2020 Jul;27:706–715. |
dc.identifier.issn | 1880-4233 |
dc.identifier.uri | https://hdl.handle.net/11351/6325 |
dc.description | Eribulina; Càncer de mama metastàsic; Supervivència global |
dc.description.sponsorship | This work was supported by Eisai Inc., Woodcliff Lake, NJ, USA. The sponsor (Eisai Inc.) participated in the design of this analysis, data analysis, data interpretation, manuscript review, manuscript approval, and decision to submit for publication. Medical writing assistance was provided by Jessica Pannu, PharmD, of Oxford PharmaGenesis Inc., Newtown, PA, USA, with funding provided by Eisai Inc. |
dc.language.iso | eng |
dc.publisher | Springer |
dc.relation.ispartofseries | Breast Cancer;27 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Mama - Càncer - Tractament |
dc.subject | Anàlisi de supervivència (Biometria) |
dc.subject.mesh | Breast Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Progression-Free Survival |
dc.title | High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician’s choice—in the EMBRACE study |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1007/s12282-020-01067-2 |
dc.subject.decs | neoplasias de la mama |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | supervivencia libre de progresión |
dc.relation.publishversion | https://doi.org/10.1007/s12282-020-01067-2 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Miyoshi Y] Department of Surgery, Division of Breast and Endocrine Surgery, Hyogo College of Medicine, Mukogawa-cho 1-1, Nishinomiya, Hyogo 663-8501, Japan. [Yoshimura Y, Muramoto K, Sugawara M] Eisai Co., Ltd., Koishikawa, Bunkyo-ku, Tokyo, Japan. [Saito K, Alexis K] Eisai Inc., Woodclif Lake, NJ, USA. [Cortes J] IOB Institute of Oncology, Quironsalud Group, Madrid, Barcelona, Spain. Breast Cancer Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 32133606 |
dc.identifier.wos | 000544235400019 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |